Oral PMPA nucleotide analog data

GILD announced Phase I/II findings with PMPA as monotherapy, with a substantial decrease in HIV RNA levels at each of three dose levels demonstrated in 36 infected patients. The agent was well tolerated.

Once daily dosing was at 75, 150, and 300 mg. Plasma HIV RNA dropped from baseline, after 28 days, by a median of 0.32 log in the 75 mg group (p=0.06), by 0.44 log after 150 mg (p=0.008), and 1.22 log in the 300 mg group (p=0.003), as compared to a median decrease of 0.06 log in the placebo group. ...